Table 4.
Sensitivity analysis according to definition of risk period before, during, and after treatment with methylphenidate
| Risk period | Arrhythmias | Hypertension | Myocardial infarction | Ischemic stroke | Heart failure | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No of patients | RR (95% CI)* | No of patients | RR (95% CI)* | No of patients | RR (95% CI)* | No of patients | RR (95% CI)* | No of patients | RR (95% CI)* | ||||||
| Primary analyses | |||||||||||||||
| Unexposed | 630 | 1 | 304 | 1 | 42 | 1 | 57 | 1 | 40 | 1 | |||||
| Exposed | 234 | 1.61 (1.48 to 1.74) | 92 | 1.07 (0.94 to 1.22) | 10 | 1.33 (0.90 to 1.98) | 10 | 0.70 (0.49 to 1.01) | 4 | 0.54 (0.30 to 0.96) | |||||
| Secondary analyses | |||||||||||||||
| Unexposed | 481 | 1 | 252 | 1 | 37 | 1 | 42 | 1 | 33 | 1 | |||||
| Exposed | 234 | 1.85 (1.72 to 1.99) | 92 | 1.12 (1.00 to 1.26) | 10 | 1.69 (1.20 to 2.40) | 10 | 0.88 (0.63 to 1.23) | 4 | 0.41 (0.23 to 0.73) | |||||
| Pre-risk period (days before treatment with methylphenidate) | |||||||||||||||
| 31-60 | 38 | 2.76 (2.48 to 3.06) | 14 | 2.04 (1.73 to 2.41) | 1 | 1.47 (0.83 to 2.62) | 6 | 5.55 (4.17 to 7.39) | 1 | NA | |||||
| 1-30 | 23 | 1.75 (1.53 to 2.01) | 6 | 1.11 (0.88 to 1.41) | 1 | 1.34 (0.76 to 2.38) | 1 | 1.46 (0.82 to 2.59) | 4 | 4.73 (3.20 to 6.98) | |||||
| Same day | 34 | 6.94 (6.06 to 7.95) | 13 | 1.44 (2.70 to 4.38) | 1 | NA | 5 | 4.70 (2.59 to 8.51) | 1 | 7.41 (3.70 to 14.84) | |||||
| Time (days) after start of methylphenidate | |||||||||||||||
| 1-3 | 24 | 2.72 (2.39 to 3.09) | 6 | 1.16 (0.91 to 1.48) | 0 | NA | 1 | 1.64 (0.90 to 2.97) | 0 | NA | |||||
| 4-7 | 26 | 2.17 (1.91 to 2.47) | 11 | 1.48 (1.22 to 1.79) | 0 | NA | 0 | NA | 0 | NA | |||||
| 8-14 | 35 | 1.80 (1.61 to 2.02) | 8 | 0.64 (0.51 to 0.80) | 3 | 2.79 (1.74 to 4.47) | 3 | 2.07 (1.41 to 3.05) | 1 | 1.02 (0.51 to 2.05) | |||||
| 15-28 | 45 | 1.75 (1.58 to 1.94) | 19 | 1.19 (1.02 to 1.39) | 2 | 2.18 (1.38 to 3.44) | 0 | NA | 1 | 1.12 (0.56 to 2.22) | |||||
| 29-56 | 51 | 2.08 (1.88 to 2.29) | 18 | 1.04 (0.88 to 1.22) | 3 | 2.89 (1.93 to 4.32) | 4 | 1.42 (0.99 to 2.04) | 0 | NA | |||||
| >56 | 53 | 1.38 (1.24 to 1.53) | 30 | 1.31 (1.13 to 1.52) | 2 | 0.75 (0.39 to 1.41) | 2 | 0.54 (0.33 to 0.87) | 2 | 0.21 (0.09 to 0.48) | |||||
| Washout period (days after treatment) | |||||||||||||||
| 1-3 | 14 | 1.75 (1.48 to 2.07) | 6 | 1.04 (0.78 to 1.40) | NA | NA | 1 | 1.96 (1.08 to 3.55) | 1 | 3.46 (1.74 to 6.89) | |||||
| 4-7 | 16 | 2.20 (1.89 to 2.57) | 8 | 1.85 (1.48 to 2.32) | 1 | 3.41 (1.88 to 6.20) | 1 | 1.98 (1.10 to 3.58) | 0 | NA | |||||
| 8-14 | 24 | 2.69 (2.36 to 3.07) | 5 | 1.10 (0.85 to 1.43) | 1 | 2.99 (1.65 to 5.42) | 1 | 1.58 (0.87 to 2.85) | 0 | NA | |||||
NA=not applicable.
*Rate ratio adjusted for age, comorbidity, and comedication in time varying method.